Yardley, PA, United States of America

Manga R Gudipati


Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 34(Granted Patents)


Location History:

  • Yardley, PA (US) (2003)
  • Hatfield, PA (US) (2003)

Company Filing History:


Years Active: 2003

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Manga R Gudipati

Introduction

Manga R Gudipati is an accomplished inventor based in Yardley, PA (US). He holds 2 patents that contribute significantly to the field of pharmaceuticals. His work primarily focuses on developing formulations that address critical health issues such as hypertension and heart failure.

Latest Patents

Manga R Gudipati's latest patents include the "Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation." This invention relates to a specific compound that blocks angiotensin II receptors, which is essential for treating hypertension, congestive heart failure, and renal failure. Another notable patent is for "bioenhanced formulations comprising eprosartan in oral solid dosage form." This invention also aims to improve the efficacy of eprosartan in treating similar health conditions.

Career Highlights

Manga R Gudipati is associated with SmithKline Beecham Corporation, where he has made significant contributions to pharmaceutical research and development. His innovative approaches have led to advancements in drug formulations that enhance patient outcomes.

Collaborations

Manga has collaborated with notable coworkers such as Gopadi M Venkatesh and John Michael Jushchyshyn. Their teamwork has fostered an environment of innovation and excellence in their projects.

Conclusion

Manga R Gudipati's contributions to the field of pharmaceuticals through his patents and collaborations highlight his commitment to improving healthcare solutions. His work continues to impact the treatment of critical health conditions effectively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…